| NCT ID | NCT06903845 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dong-Ju Choi |
| Condition | Atrial Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-03-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this clinical trial is to evaluate whether the medication reminder app and video call can improve medication adherence to apixaban in patients with AF and comorbidities. Patients with AF and comorbid heart disease taking apixaban who meet the inclusion criteria will be randomised 1:1 to a treatment arm using a medication reminder app and bi-weekly video education and a control arm using the medication reminder app alone to compare medication adherence. Patients in both groups will use the medication app, but only the treatment group will receive additional education and feedback via video call every two weeks to reinforce the use of the medication app and medication reminders with video education. The study aims to assess the change in adherence between the two groups at week 8.
Eligibility Criteria
Participants must meet all of the following criteria: Adults aged 19 years or older with a diagnosis of atrial fibrillation (AF) Presence of at least one of the following cardiovascular or metabolic comorbidities: A. Heart failure B. Hypertension C. Coronary artery disease D. Peripheral arterial disease E. Diabetes mellitus F. Stroke G. Other cardiac diseases requiring treatment Currently taking or planning to initiate oral anticoagulation therapy with apixaban Able to use a smartphone with an Android operating system Voluntarily provided written informed consent to participate in the clinical trial after being adequately informed of its purpose, procedures, and potential risks 2\. Exclusion Criteria Participants will be excluded if any of the following conditions apply: Creatinine clearance (CCr) \< 15 mL/min Presence of moderate to severe mitral stenosis History of mitral valve repair or replacement Clinically significant history of alcohol or substance abuse Deemed by the investigator to be legally or psychologically unsuitable for participation in the clinical trial Participation in another clinical trial involving investigational drugs within 4 weeks prior to screening Declines or is unwilling to provide informed consent for participation in this study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06903845 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06903845 currently recruiting?
Yes, NCT06903845 is actively recruiting participants. Contact the research team at minjae1677@gmail.com for enrollment information.
Where is the NCT06903845 trial being conducted?
This trial is being conducted at Seongnam, South Korea.
Who is sponsoring the NCT06903845 clinical trial?
NCT06903845 is sponsored by Dong-Ju Choi. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.